Loading
Lung Cancer Research Studies / Lung Cancer Treatments and Mutations · Journal article
Frontiers in Immunology · August 11, 2026
Encouraging direction, but not yet definitive.
This open-label, single-arm phase 2 trial of iparomlimab and tuvonralimab (QL1706) plus chemotherapy in 40 patients with ES-SCLC reports a confirmed ORR of 92.1%, median PFS of 6.0 months, and median OS of 15.8 months, with a safety profile dominated by hematologic toxicity and low-grade immune-related events. The results are promising but lack a comparator arm and require phase 3 validation before clinical adoption can be recommended.
Single-arm, multicenter, open-label phase 2 trial. Patients with extensive-stage small cell lung cancer (ES-SCLC) eligible for first-line treatment.. Intervention: Iparomlimab and tuvonralimab (QL1706, a PD-1 and CTLA-4 monoclonal antibody combination) plus carboplatin and etoposide for 4–6 cycles, followed by QL1706 maintenance. n = 40. Multicenter study; specific sites and countries not detailed in the abstract..
Confirmed objective response rate was 92.1% (95% CI 78.6–98.3) in 38 efficacy-evaluable patients Median progression-free survival was 6.0 months (95% CI 5.4–8.3) Median overall survival was 15.8 months (95% CI 11.4–20.0)
All 40 patients experienced at least one treatment-related adverse event; 9 patients (22.5%) experienced immune-related adverse events, mostly grade 1–2 Grade 3 immune-related adverse events occurred in 2 patients (5.0%); no TRAEs led to death or discontinuation
While the ORR and survival outcomes are numerically encouraging, the single-arm design precludes direct comparison with standard chemotherapy alone or other immunochemotherapy regimens. Clinicians should await phase 3 results before considering this combination a preferred first-line option for ES-SCLC.
Single-arm phase 2 trial with encouraging response and survival outcomes in ES-SCLC, but lacks a comparator arm and requires phase 3 validation to establish practice-changing impact.
As stated by the source record.
Quoted from the source exactly as published.
While the ORR and survival outcomes are numerically encouraging, the single-arm design precludes direct comparison with standard chemotherapy alone or other immunochemotherapy regimens. Clinicians should await phase 3 results before considering this combination a preferred first-line option for ES-SCLC.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Iparomlimab and tuvonralimab (QL1706) is a MabPair product consisting of PD-1 and CTLA-4 monoclonal antibodies. This single-arm, multicenter, phase 2 study assessed the safety and efficacy of first-line QL1706 plus etoposide and carboplatin (EC) for extensive-stage small cell lung cancer (ES-SCLC). Methods Patients with ES-SCLC received QL1706 plus EC every 3 weeks for 4–6 cycles, followed by QL1706 maintenance therapy until disease progression. Primary endpoint was safety. Results Among 40 patients enrolled, all patients experienced at least one treatment-related adverse event (TRAE). Most TRAEs were hematologic toxicities. Nine patients (22.5%) experienced immune-related adverse events, mostly grade 1–2, with a median time from treatment to the first irAE of 3.1 months (range 0.1–11.0) with a median duration of the irAEs of 1.3 months (range 0.1–10.7). Grade 3 irAEs occurred in 2 (5.0%) patients, one case each for rash and vomiting. No TRAEs leading to death or treatment discontinuation occurred. In 38 patients evaluable for efficacy, the confirmed objective response rate was 92.1% (95% confidence interval [CI] 78.6–98.3). Median progression-free survival (PFS) and overall survival (OS) were 6.0 months (95% CI 5.4–8.3) and 15.8 months (95% CI 11.4–20.0), respectively. In exploratory analyses, the median OS was 20.5 months (95% CI 11.4–not evaluable) in patients with a good lung immune prognostic index status and 19.7 months (95% CI 11.4–22.5) in patients with a combined positive score 1. Conclusions QL1706 plus EC was well-tolerated and showed promising anti-tumor activity and survival benefit in first-line treatment for ES-SCLC, and warranted further validation in larger scale phase 3 studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.